IBDEI2KM ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,41031,1,4,0)
 ;;=4^A81.9
 ;;^UTILITY(U,$J,358.3,41031,2)
 ;;=^5000414
 ;;^UTILITY(U,$J,358.3,41032,0)
 ;;=A81.09^^152^2020^8
 ;;^UTILITY(U,$J,358.3,41032,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41032,1,3,0)
 ;;=3^Creutzfeldt-Jakob Disease NEC
 ;;^UTILITY(U,$J,358.3,41032,1,4,0)
 ;;=4^A81.09
 ;;^UTILITY(U,$J,358.3,41032,2)
 ;;=^5000410
 ;;^UTILITY(U,$J,358.3,41033,0)
 ;;=A81.00^^152^2020^9
 ;;^UTILITY(U,$J,358.3,41033,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41033,1,3,0)
 ;;=3^Creutzfeldt-Jakob Disease,Unspec
 ;;^UTILITY(U,$J,358.3,41033,1,4,0)
 ;;=4^A81.00
 ;;^UTILITY(U,$J,358.3,41033,2)
 ;;=^5000409
 ;;^UTILITY(U,$J,358.3,41034,0)
 ;;=A81.01^^152^2020^10
 ;;^UTILITY(U,$J,358.3,41034,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41034,1,3,0)
 ;;=3^Creutzfeldt-Jakob Disease,Variant
 ;;^UTILITY(U,$J,358.3,41034,1,4,0)
 ;;=4^A81.01
 ;;^UTILITY(U,$J,358.3,41034,2)
 ;;=^336701
 ;;^UTILITY(U,$J,358.3,41035,0)
 ;;=A81.89^^152^2020^7
 ;;^UTILITY(U,$J,358.3,41035,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41035,1,3,0)
 ;;=3^Atypical Virus Infections of CNS NEC
 ;;^UTILITY(U,$J,358.3,41035,1,4,0)
 ;;=4^A81.89
 ;;^UTILITY(U,$J,358.3,41035,2)
 ;;=^5000413
 ;;^UTILITY(U,$J,358.3,41036,0)
 ;;=A81.2^^152^2020^27
 ;;^UTILITY(U,$J,358.3,41036,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41036,1,3,0)
 ;;=3^Progressive Multifocal Leukoencephalopathy
 ;;^UTILITY(U,$J,358.3,41036,1,4,0)
 ;;=4^A81.2
 ;;^UTILITY(U,$J,358.3,41036,2)
 ;;=^5000411
 ;;^UTILITY(U,$J,358.3,41037,0)
 ;;=B20.^^152^2020^17
 ;;^UTILITY(U,$J,358.3,41037,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41037,1,3,0)
 ;;=3^HIV Disease w/ Dementia w/ Behavioral Disturbances
 ;;^UTILITY(U,$J,358.3,41037,1,4,0)
 ;;=4^B20.
 ;;^UTILITY(U,$J,358.3,41037,2)
 ;;=^5000555^F02.81
 ;;^UTILITY(U,$J,358.3,41038,0)
 ;;=B20.^^152^2020^18
 ;;^UTILITY(U,$J,358.3,41038,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41038,1,3,0)
 ;;=3^HIV Disease w/ Dementia w/o Behavioral Disturbances
 ;;^UTILITY(U,$J,358.3,41038,1,4,0)
 ;;=4^B20.
 ;;^UTILITY(U,$J,358.3,41038,2)
 ;;=^5000555^F02.80
 ;;^UTILITY(U,$J,358.3,41039,0)
 ;;=F10.27^^152^2020^1
 ;;^UTILITY(U,$J,358.3,41039,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41039,1,3,0)
 ;;=3^Alcohol Dependence w/ Alcohol-Induced Persisting Dementia
 ;;^UTILITY(U,$J,358.3,41039,1,4,0)
 ;;=4^F10.27
 ;;^UTILITY(U,$J,358.3,41039,2)
 ;;=^5003095
 ;;^UTILITY(U,$J,358.3,41040,0)
 ;;=F19.97^^152^2020^29
 ;;^UTILITY(U,$J,358.3,41040,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41040,1,3,0)
 ;;=3^Psychoactive Substance Use w/ Persisting Dementia NEC
 ;;^UTILITY(U,$J,358.3,41040,1,4,0)
 ;;=4^F19.97
 ;;^UTILITY(U,$J,358.3,41040,2)
 ;;=^5003465
 ;;^UTILITY(U,$J,358.3,41041,0)
 ;;=F03.90^^152^2020^15
 ;;^UTILITY(U,$J,358.3,41041,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41041,1,3,0)
 ;;=3^Dementia w/o Behavioral Disturbance,Unspec
 ;;^UTILITY(U,$J,358.3,41041,1,4,0)
 ;;=4^F03.90
 ;;^UTILITY(U,$J,358.3,41041,2)
 ;;=^5003050
 ;;^UTILITY(U,$J,358.3,41042,0)
 ;;=G30.0^^152^2020^2
 ;;^UTILITY(U,$J,358.3,41042,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41042,1,3,0)
 ;;=3^Alzheimer's Disease w/ Early Onset
 ;;^UTILITY(U,$J,358.3,41042,1,4,0)
 ;;=4^G30.0
 ;;^UTILITY(U,$J,358.3,41042,2)
 ;;=^5003805
 ;;^UTILITY(U,$J,358.3,41043,0)
 ;;=G30.1^^152^2020^3
 ;;^UTILITY(U,$J,358.3,41043,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41043,1,3,0)
 ;;=3^Alzheimer's Disease w/ Late Onset
